Menu
Montecito
American Riviera
Loading...
You are here:  Home  >  'Amgen'  -  Page 50
Latest

Amgen bipolar about biosimilars

By   /  Friday, December 4th, 2015  /  Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen bipolar about biosimilars

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Diabetes drug may be game changer

By   /  Friday, November 27th, 2015  /  Central Coast Health Watch, Latest news, Top Stories  /  Comments Off on Diabetes drug may be game changer

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen asks FDA to approve biosimilar drug

By   /  Wednesday, November 25th, 2015  /  Central Coast Health Watch, Latest news, Top Stories  /  Comments Off on Amgen asks FDA to approve biosimilar drug

Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →

Read More →
Latest

European regulators approve Amgen cancer drug Kyprolis

By   /  Thursday, November 19th, 2015  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on European regulators approve Amgen cancer drug Kyprolis

Thousand Oaks-based Amgen scored another major victory Nov. 19. European regulators approved experimental drug Kyprolis on Thursday for patients who have received at least one prior treatment for multiple-myeloma. Kyprolis was the cornerstone of Amgen’s $10.4 billion buyout of Onyx Pharmaceuticals in 2013. Multiple-myeloma is a form of blood cancer that forms in plasma cells Read More →

Read More →
Latest

FDA to review Amgen’s new kidney disease dug

By   /  Friday, November 6th, 2015  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA to review Amgen’s new kidney disease dug

Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →

Read More →
Latest

Amgen’s third quarter earnings beat Wall Street expectations

By   /  Wednesday, October 28th, 2015  /  Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen’s third quarter earnings beat Wall Street expectations

Thousand Oaks biotech giant Amgen blew Wall Street away when it released third quarter earnings on Oct. 28. Amgen beat analyst revenue estimates by posting revenues of $5.72 billion, compared to the $5.23 billion analysts expected. That’s up from about $5 billion during last year’s third quarter. Net income increased to $1.86 billion during the Read More →

Read More →
Latest

FDA OKs Amgen skin cancer drug Imlygic

By   /  Tuesday, October 27th, 2015  /  Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on FDA OKs Amgen skin cancer drug Imlygic

The U.S. Food and Drug Administration on Oct. 27 approved Amgen’s cancer immunotherapy drug Imlygic for use in patients with the most deadly types of skin cancer. Imlygic, which is the first immunotherapy like this to gain approval for use in the U.S., is a genetically modified herpes virus that is designed to replicate itself Read More →

Read More →